Heterogeneous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to staurosporine-induced apoptosis, expression of Bcl-2 family members, and caspase activation
- 1 March 2000
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 42 (4) , 260-273
- https://doi.org/10.1002/(sici)1097-0045(20000301)42:4<260::aid-pros3>3.0.co;2-0
Abstract
The goal of this work was to identify mechanisms for the inability of metastatic prostate cancer cells to engage the apoptotic pathway following hormonal or cytotoxic therapy. Genotypically diverse cell lines isolated from patients with metastatic disease were used. The LNCaP and TsuPr(1) lines exhibited quintessential apoptotic features in response to the pleiotropic apoptotic inducer staurosporine (STS): rapid cytochrome c translocation to the cytosol, proteolytic processing and catalytic activation of caspase-3 and -7, proteolytic inactivation of the death substrates DNA fragmentation factor (DFF) and poly-ADP-ribose polymerase (PARP), and TUNEL-positive polyfragmented nuclei. In contrast, DU-145 and PC-3 cells exhibited few, if any, of these features, while appearing necrotic by confocal microscopy. The presence of caspase-3 and -7 without proteolytic processing suggested that the apoptotic blockade was upstream of executioner caspases in these resistant cell lines. To identify the locus of this block, Western blot analysis of cytochrome c subcellular localization and of pro- and antiapoptotic Bcl-2 family members was performed, and suggested that heterogeneous expression of these proteins might be the underlying mechanism for apoptotic resistance to STS in these cell lines. Thus, the absence of the proapoptotic Bax in DU-145 cells indicated a mechanism for apoptotic resistance of these cells. Similarly, decreased Bax expression during STS treatment, coupled with overexpression of the antiapoptotic Bcl-xL and inability to translocate cytochrome c to the cytosol, provided a mechanism for the insensitivity of PC-3 cells. These observations suggest that activation of the apoptotic machinery in metastatic prostate cancer cell lines may be determined by expression levels of Bcl-2 family members, by the ability of cytochrome c to translocate to the cytosol, and by the ability of the caspase pathway to react in response to activation of the mitochondrial phase. Prostate 42:260–273, 2000.Keywords
This publication has 56 references indexed in Scilit:
- Bax and Adenine Nucleotide Translocator Cooperate in the Mitochondrial Control of ApoptosisScience, 1998
- Distinct cleavage products of nuclear proteins in apoptosis and necrosis revealed by autoantibody probesCell Death & Differentiation, 1998
- Green Tea Constituent Epigallocatechin-3-Gallate and Induction of Apoptosis and Cell Cycle Arrest in Human Carcinoma CellsJNCI Journal of the National Cancer Institute, 1997
- Processing/Activation of At Least Four Interleukin-1β Converting Enzyme–like Proteases Occurs during the Execution Phase of Apoptosis in Human Monocytic Tumor CellsThe Journal of cell biology, 1997
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997
- Different Cleavage Pattern for Poly(ADP-Ribose) Polymerase during Necrosis and Apoptosis in HL-60 CellsBiochemical and Biophysical Research Communications, 1996
- Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome cPublished by Elsevier ,1996
- Separate pools of endonuclease activity are responsible for internucleosomal and high molecular mass DNA fragmentation during apoptosisBiochemistry and Cell Biology, 1994
- Androgen receptors in endocrine‐therapy‐resistant human prostate cancerInternational Journal of Cancer, 1991
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989